Advertisement

Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes

  • Janet R. Vos
  • Lisette Giepmans
  • Claas Röhl
  • Nicoline Geverink
  • Nicoline Hoogerbrugge
  • ERN GENTURIS
Open Access
Short Communication
  • 290 Downloads

Abstract

Approximately 27–36 million patients in Europe have one of the ~ 5.000–8.000 known rare diseases. These patients often do not receive the care they need or they have a substantial delay from diagnosis to treatment. In March 2017, twenty-four European Reference Networks (ERNs) were launched with the aim to improve the care for these patients through cross border healthcare, in a way that the medical knowledge and expertise travels across the borders, rather than the patients. It is expected that through the ERNs, European patients with a rare disease get access to expert care more often and more quickly, and that research and guideline development will be accelerated resulting in improved diagnostics and therapies. The ERN on Genetic Tumour Risk Syndromes (ERN GENTURIS) aims to improve the identification, genetic diagnostics, prevention of cancer, and treatment of European patients with a genetic predisposition for cancer. The ERN GENTURIS focuses on syndromes such as hereditary breast cancer, hereditary colorectal cancer and polyposis, neurofibromatosis and more rare syndromes e.g. PTEN Hamartoma Tumour Syndrome, Li Fraumeni Syndrome and hereditary diffuse gastric cancer.

Keywords

Hereditary cancer Cross border health care European Reference Network Rare diseases Syndrome Genetic 

The pan-European approach to rare diseases

The current state of rare diseases in Europe

Health systems in the European Union (EU) aim to provide high-quality, cost-effective care. For rare and complex diseases, this is a challenge due to the fragmented knowledge about these diseases [1, 2]. Hence, patients with a rare disease often do not receive the care they need or experience significant delay to the correct diagnosis and treatment. Across Europe there is substantial variation in health care for patients with a rare disease, especially considering prognosis, quality of life, healthcare costs, available guidelines and patient information. A rare disease is defined as a condition that affects fewer than 1 in 2,000 people. It is estimated that 6–8% of all people someday in their lives will face a rare disease [1]. In the EU there are approximately 27–36 million people who experience daily suffering from one of the 5000 to 8000 known rare diseases.

The ERNs are focused on providing a system of care, in which the medical knowledge and expertise travels across the borders, rather than the patients. In case it is unavoidable the patient will travel to the nearest foreign expertise centre. In addition to care, the ERNs provide a platform for education, training, patient empowerment, the development of guidelines and research activities.

The objective of European Reference Networks

European reference networks (ERNs) are virtual networks of medical experts from all over Europe. ERNs are focused on rare or complex diseases that require highly specialized treatments and a combined effort of expert knowledge and resources. The ERNs aim to improve the care of patients with a rare disease [3, 4]. The European Commission Expert Group on Rare Diseases, in collaboration with EURORDIS, a European alliance of rare disease patient organisations, has identified themes in which all rare diseases will be classified. In March 2017, 24 ERNs were appointed to these themes by the Board of Member States of the European Union, which oversees the ERNs [3, 5]. These 24 ERNs unite more than 900 expert teams from more than 300 hospitals and 150 patient representatives from 25 European member states in the area of one or more themes [4, 5, 6]. At national level, many expertise centres for rare disease have been recognized by their government in the last few years. The procedures and criteria for the establishment of an ERN and the selection of members are regulated in EU legislation. To become a member of an ERN, a hospital or healthcare institute needs national endorsement and must meet a number of general requirements set by the European Commission (such as recognition by the national government) and a number of theme-specific criteria for each ERN (such as minimum number of patients and demonstrable facts related to expertise).

Information and access to European Reference Networks

In the years to follow a healthcare professional in the EU can use the expertise of the relevant ERN via one of the (national) expertise centres involved in the ERN of interest [7]. Patients can request advice from the network through their local medical specialist. In practice, this means that the healthcare professional refers the patient to the nearest expertise centre in their own country, and then this expertise centre will, if necessary, present the case to other experts in the ERN.

The patients will be asked informed consent by their referring healthcare professional for discussing their case via the Clinical Patient Management System: the secure web-based application functioning as the platform where healthcare professionals from the European Reference Networks (ERNs) discuss real patient cases. The informed consent form enables patients to participate and profit from the ERN at 3 levels: (1) to have their medical data shared with healthcare professionals in the ERN so that they may work together to support the patient’s care; (2) to have their de-identified data being included in one or more ERN database or registry; (3) to be contacted about the possibility to participate in a specific research project.

The ERN for genetic tumour risk syndromes (ERN GENTURIS)

The state of affairs in the field of hereditary cancer in Europe

Hereditary tumour syndromes are often characterized by an increased risk for common tumours such as breast and colorectal cancer, by the occurrence of cancer at a younger age and by tumours at multiple locations. More than forty different forms of hereditary cancer syndromes are known [8]. Currently in Europe the majority of patients with a genetic tumour risk syndrome is not yet recognized as such [9, 10, 11, 12, 13]. However, if the hereditary predisposition is known in time, risk management options can be provided to prevent cancer from occurring or to detect cancer at an early stage. Often this is related to a better prognosis in both the patient and his/her family as also other family member could have inherited the genetic predisposition causing the syndrome. In addition, patients with hereditary cancer can benefit from a treatment adapted to the hereditary predisposition [14, 15, 16, 17, 18].

The role of ERN GENTURIS in the field of hereditary cancer

The European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) is the ERN in the field of hereditary cancer. ERN GENTURIS aims at all patients in Europe with a known hereditary cancer predisposition by integrated, multidisciplinary activities in the fields of care, guidelines, education and research directed towards improved identification, genetic diagnostics, cancer prevention and treatment [19].

ERN GENTURIS is coordinated by N. Hoogerbrugge, MD, PhD from the Radboud university medical center and currently brings together 23 centres in the field of hereditary cancer from 12 European member states, as well as seven patient representatives [19]. Within ERN GENTURIS, the rare or complex syndromes are divided into four themes: (1) Neurofibromatosis; (2) Hereditary colorectal cancer and Polyposis; (3) Hereditary breast and ovarian cancer; (4) Other rare, mainly malignant, hereditary tumour risk syndromes such as PTEN Hamartoma tumour Syndrome (PHTS), Li-Fraumeni syndrome, hereditary melanoma (FAMM), and hereditary stomach cancer.

The governmental structure of ERN GENTURIS includes a National Coordinators Board consisting of national representatives for each of the participating member states. The national coordinators act as contact with all HCPs, national patient and professional organizations and networks in their country. They will disseminate centrally established output and if necessary “translate” this into national products. For member states where no HCP is found that fulfil the GENTURIS criteria, an affiliated partner will act as national representative for ERN GENTURIS. In this way, all member states will be involved in ERN GENTURIS and will have access to guidelines and registries. The ERN will collaborate with other European stakeholders like current scientific collaborations, medical societies and patient representatives.

More information about ERN GENTURIS and the participating expertise centres and partners and their specific expertise can be found on the website of ERN GENTURIS (http://www.genturis.eu).

Network activities

The network is organized via closed biannual network meetings and monthly executive committee meetings and task force meetings. Task forces are formulated to organize and stimulate six key functions of the ERN: (1) Coordination and management, (2) Organization of care, (3) Guidelines, outcomes and quality, (4) Education and training, (5) Research, data registration and grants, and (6) Patient empowerment, communication and dissemination.

Organization of care The ERN GENTURIS is an expert reference network for patients with or suspected of having a genetic tumour predisposition syndrome. Only a physician can consult the network and/or refer a patient with any question related to the health care pathway of these syndromes. This includes topics as identification, diagnostics, treatment and risk management. A triage system is in place to manage these incoming requests by complexity, and facilitate a suitable action from an answer from an individual local or international ERN expert to an answer after multidisciplinary team discussion among experts within the ERN GENTURIS.

Guidelines The ERN GENTURIS will use her expertise to develop guidelines for care. The approach used to develop guidelines will be based on the NICE process, including the GRADE, AGREE, and Delphi methodology. For each syndrome a committee will be selected, consisting of a core group and an extended group. The core group will consist of three people who cover the defined disciplines of the core multidisciplinary team of the syndrome. The extended group will cover relevant disciplines of the extended multidisciplinary team, including a patient representative. Each guideline will relate to one of six modules of the clinical pathways: (1) General description of the syndrome, (2) Identification of patients, (3) Surveillance and follow-up, (4) Treatment of symptoms, (5) Prophylactic treatment, and (6) Psychosocial counselling.

Registry The ERN GENTURIS registry covers a standardised minimal dataset on genotype and phenotype which will be captured following international classifications and ontology’s. Patients who were referred to the ERN GENTURIS and who gave permission on their ERN informed consent form for data registration will be included in the registry. Rules of governance are being established that will include procedures for reviewing data requests, data access and data sharing of pseudonymised data.

Conclusion

In the near future medical specialists can call upon the ERNs with healthcare questions related to patients with rare or complex diseases. European collaboration is essential, both for the care that is currently needed as for the continuous and sustainable improvement of care. In this respect, the ERNs will provide an important stimulus to improve the life of many patients with rare diseases.

Notes

Acknowledgements

ERN GENTURIS: The European Reference Network Genetic Tumour Risk Syndromes (ERN GENTURIS) consists of the following participating centers and their representatives: Radboud University Medical Center, Nijmegen, Netherlands: Nicoline Hoogerbrugge, Marjolijn Ligtenberg, Marleen Kets; University Medical Center Groningen, Groningen, Netherlands: Rolf Sijmons; Genomic Medicine, Central Manchester Foundation Trust, Manchester, United Kingdom: Gareth Evans, Emma Woodward; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom: Marc Tischkowitz, Eamonn Maher; Medizinisch Genetisches Zentrum, Munich, Germany: Verena Steinke-Lange, Elke Holinski-Feder; Rouen University Hospital, Rouen, France: Thierry Frebourg, Claude Houdayer; Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom: Rosalie E. Ferner; Pomeranian Medical University-University Clinical Hospital no 1, Szczecin, Poland: Jan Lubinski, Karolina Ertmanska; Karolinska University Hospital, Stockholm, Sweden: Svetlana Bajalica Lagercrantz, Emma Tham; Hospital Germans Trias I Pujol - lnstitut Catala d’Oncologia, Barcelona, Spain: Ignacio Blanco Guillermo, Gabriel Capella, Joan Brunet Vidal, Conxi Lázaro, Judith Balmaña; University Hospital Liege, Liege, Belgium: Vincent Bours; University Hospital Leuven, Leuven, Belgium: Eric Legius; University Hospital Henri Mondor-National Referral Center, Créteil, France: Pierre Wolkenstein; University of Pécs, Pécs, Hungary: Bela Melegh; Porto Comprehensive Cancer Center, Porto, Portugal: Carla Oliveira, Manuel Teixeira; Ghent University Hospital, Ghent, Belgium: Bruce Poppe, Kathleen Claes; Hospital Sant Joan de Déu, Barcelona, Spain: Hector Salvador Hernandez; Center for Hereditary Tumor Syndromes; University Hospital Bonn, Bonn, Germany: Stefan Aretz, Isabel Spier; ENCORE - NF1 Expertise Centre, Erasmus Medical Center, Rotterdam, Netherlands: Rianne Oostenbrink; Institute of Oncology Ljubljana, Ljubljana, Slovenia: Mateja Krajc, Ana Blatnik; Hereditary Cancer Syndrome Center Dresden, Dresden, Germany: Evelin Schröck; The hospital District of Southwest Finland, Turku University Hospital, Turku, Finland: Sirkku Peltonen, Marja Hietala; Institut Curie, Paris, France: Chrystelle Colas.

Compliance with ethical standards

Conflict of interest

None to declare.

References

  1. 1.
    Puiu M, Dan D (2010) Rare diseases, from European resolutions and recommendations to actual measures and strategies. Maedica 5(2):128–131PubMedPubMedCentralGoogle Scholar
  2. 2.
    European Union (2009) Publication sheet C151 of the Europese Union. ISSN 1725–2474Google Scholar
  3. 3.
    European Commission Rare disease policy. https://ec.europa.eu/health/non_communicable_diseases/rare_diseases_en. 5 Oct 2018
  4. 4.
    Eurordis. European Patient Advocacy Groups (ePAGs). http://www.eurordis.org/content/epags. Accessed 5 Oct 2018
  5. 5.
    Wijnen R, Anzelewicz SM, Petersen C, Czauderna P (2017) European Reference Networks: share, care, and cure-future or dream? Eur J Pediatric Surg 27(5):388–394CrossRefGoogle Scholar
  6. 6.
    European Commision (2017) European reference networks. Working for patients with rare, low-prevalence and complex disease. https://ec.europa.eu/health/sites/health/files/ern/docs/2017_brochure_en.pdf
  7. 7.
    Heon-Klin V (2017) European Reference networks for rare diseases: what is the conceptual framework? Orphanet journal of rare diseases 12(1):137.  https://doi.org/10.1186/s13023-017-0676-3 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Garber JE, Offit K (2005) Hereditary cancer predisposition syndromes. J Clin Oncol 23(2):276–292CrossRefGoogle Scholar
  9. 9.
    Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet 152a(2):327–332CrossRefGoogle Scholar
  10. 10.
    Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE (2016) Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 34(13):1460–1468.  https://doi.org/10.1200/jco.2015.65.0747 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lerner-Ellis J, Khalouei S, Sopik V, Narod SA (2015) Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Exp Rev Anticancer Therapy 15(11):1315–1326CrossRefGoogle Scholar
  12. 12.
    Dekker N, Hermens RP, Nagengast FM, van Zelst-Stams WA, Hoogerbrugge N (2013) Familial colorectal cancer risk assessment needs improvement for more effective cancer prevention in relatives. Colorectal Dis 15(4):e175–e185; discussion p.e185CrossRefGoogle Scholar
  13. 13.
    Sie AS, Mensenkamp AR, Adang EM, Ligtenberg MJ, Hoogerbrugge N (2014) Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. Ann Oncol 25(10):2001–2007CrossRefGoogle Scholar
  14. 14.
    Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rodland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Jenkins M, Green K, Lalloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Frayling IM, Plazzer JP, Pylvanainen K, Genuardi M, Mecklin JP, Moslein G, Sampson JR, Capella G (2017) Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut 66(9):1657–1664CrossRefGoogle Scholar
  15. 15.
    Kurian AW, Sigal BM, Plevritis SK (2010) Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 28(2):222–231CrossRefGoogle Scholar
  16. 16.
    Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44(2):81–88CrossRefGoogle Scholar
  17. 17.
    van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, DeGregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJ, O’Donovan M, Oliveira C, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe ST, van Dijck B, van Grieken NC, van Hillegersberg R, van Sandick JW, Vehof R, van Krieken JH, Fitzgerald RC (2015) Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 52(6):361–374CrossRefGoogle Scholar
  18. 18.
    Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, De La Chapelle A, Mecklin JP (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829–834CrossRefGoogle Scholar
  19. 19.
    European Reference Network Genetic Tumour Risk Syndromes (ERN GENTURIS). http://www.genturis.eu

Copyright information

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Janet R. Vos
    • 1
  • Lisette Giepmans
    • 2
  • Claas Röhl
    • 3
  • Nicoline Geverink
    • 4
  • Nicoline Hoogerbrugge
    • 1
    • 5
  • ERN GENTURIS
  1. 1.Department of Human GeneticsRadboud University Medical CenterNijmegenThe Netherlands
  2. 2.Research B.V, University Medical Center GroningenUniversity of GroningenGroningenThe Netherlands
  3. 3.Patient representative, European Patient Advocacy Group, European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)ViennaAustria
  4. 4.Department of UrologyRadboud University Medical CenterNijmegenThe Netherlands
  5. 5.Coordinator European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)NijmegenThe Netherlands

Personalised recommendations